Author - admin4821

Annandale, VA; September 17, 2020 CARE-ID has reached its allocated target for enrollees in its collaboration with Pfizer for clinical research to evaluate the safety and effectiveness of its SARS-CoV-2-RNA vaccine candidate against COVID-19. This is a major CARE-ID milestone in the collaboration and initially this target was thought to be the end goal of its research effort. However, Pfizer has now expanded the original study. The expansion will allow the further increase in trial population diversity, and inclusion of people with chronic, stable HIV (human immunodeficiency viruses), Hepatitis C, or Hepatitis B infection, as well as provide additional safety and efficacy data. In this expansion, Pfizer gains a particularly valuable partner given CARE-ID decades long experience in researching treatments for these particular infectious diseases.

• Read more about CARE-ID’s involvement fighting COVID-19
• For more information on the Pfizer study expansion

We don’t know when a COVID-19 vaccine will arrive, but we’re starting to know how it will be distributed. Interviews with logistics experts, immunization professionals and pharmaceutical distribution specialists, together with U.S. Centers for Disease Control and Prevention planning documents, give a clearer picture of how coronavirus vaccines will get from manufacturers into the arms of millions of Americans. “The swift and so far positive effort to create vaccines to fight COVID-19 has been remarkable, but it’s only half of the work”, said Tinglong Dai, a professor of operations management who studies health care analytics at the Johns Hopkins University. “It’s just incredible. I think the vaccine supply chain is one of the most mind-bogglingly complex supply chains ever built,” he said.

• Read entire article

Annandale, VA; September 1, 2020 Beginning in the months of July and August this year, CARE-ID committed its research experience and resources to the fight against COVID-19. In doing so, it not only continues its role in advancing medicines for a variety of infectious diseases, now it is a notable participant in expanding the science for effective COVID-19 treatments. The first step came in partnering with Lilly and Company (Lilly) to conduct a clinical research study, BLAZE-1, to evaluate the safety and effectiveness of LY-CoV555 (an antibody therapy) in patients with early mild to moderate COVID-19. The promise of this drug is to help newly diagnosed patients clear the SARS-CoV-2 virus faster. The second, very quick, step was continuing the longstanding collaboration in place with Pfizer. In this case it was to conduct clinical research to evaluate the safety and effectiveness of its SARS-CoV-2-RNA vaccine candidate against COVID-19. The promise of a vaccine against COVID-19 is nearly impossible to overestimate in today’s fight against this pandemic disease.

• Read more about CARE-ID’s involvement fighting COVID-19

Annandale, VA; August 24, 2020 CARE-ID announced today it has begun recruiting volunteers in a clinical research study to evaluate the safety and effectiveness of a vaccine candidate against COVID-19. Sponsored by Pfizer, the C4591001 (NCT04368728) is a phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-COV-2-RNA vaccine candidates against COVID-19 in health adults.

• Read more about CARE-ID’s COVID-19 Vaccine Study

Annandale, VA; August 17, 2020 CARE-ID is very pleased to report it has reached 50% of its target for participants receiving their treatment infusions. “We were not entirely sure how strong a response we’d get when we began. Starting up this study was very fast compared to other studies we’ve done in the past,” said Steve Poretz, RN, MSHA, Executive Director at CARE-ID. “Happily, the response has been very good so far for this very important clinical research study.” Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful results in the laboratory setting. As of August 14th, hundreds of participants have enrolled in the study nation-wide and have received the one-time, one-hour infusion in the outpatient setting. To continue making its progress, CARE-ID is looking for additional adults in the Northern Virginia area ages 18 or older to participate in the study who have recently tested positive for COVID-19 and are not hospitalized.

• Read more about CARE-ID’s involvement in the BLAZE-1 Study